Overview about Candida auris: What's up 12 years after its first description?

J Mycol Med. 2022 May;32(2):101248. doi: 10.1016/j.mycmed.2022.101248. Epub 2022 Jan 21.

Abstract

Candida auris has been described as an emerging yeast species during the last decade. As many as 25% of its strains may naturally exhibit multi-drug resistance to the currently available antifungal drugs. Probably due to its ability to survive more than two weeks on inert surfaces, several large outbreaks have been reported, primarily due to nosocomial transmissions. In addition, due to a rapid worldwide spreading, C. auris is now considered as a major public health threat. This review aims at describing the current knowledge about C. auris, with specific focuses on its global epidemiology, virulence features, most reliable diagnostic approaches, and the current and future therapeutic options.

Keywords: Candida auris; Diagnosis; Epidemiology; Genetic; Resistance.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida auris*
  • Candida*
  • Disease Outbreaks
  • Microbial Sensitivity Tests
  • Virulence

Substances

  • Antifungal Agents